274 related articles for article (PubMed ID: 30542932)
1. Idiopathic nephrotic syndrome and rituximab: may we predict circulating B lymphocytes recovery?
Delbet JD; Leclerc G; Ulinski T
Pediatr Nephrol; 2019 Mar; 34(3):529-532. PubMed ID: 30542932
[TBL] [Abstract][Full Text] [Related]
2. Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome.
Hogan J; Dossier C; Kwon T; Macher MA; Maisin A; Couderc A; Niel O; Baudouin V; Deschênes G
Pediatr Nephrol; 2019 Feb; 34(2):253-259. PubMed ID: 30109447
[TBL] [Abstract][Full Text] [Related]
3. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab.
Kamei K; Ogura M; Sato M; Sako M; Iijima K; Ito S
Pediatr Nephrol; 2016 Jan; 31(1):89-95. PubMed ID: 26341251
[TBL] [Abstract][Full Text] [Related]
5. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
Fujinaga S; Hirano D; Mizutani A; Sakuraya K; Yamada A; Sakurai S; Shimizu T
Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
[TBL] [Abstract][Full Text] [Related]
6. Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion.
Sato M; Kamei K; Ogura M; Ishikura K; Ito S
Clin Exp Nephrol; 2018 Feb; 22(1):110-116. PubMed ID: 28434126
[TBL] [Abstract][Full Text] [Related]
7. Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome.
Maxted AP; Dalrymple RA; Chisholm D; McColl J; Tse Y; Christian MT; Reynolds BC
Pediatr Nephrol; 2019 May; 34(5):855-863. PubMed ID: 30564878
[TBL] [Abstract][Full Text] [Related]
8. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome.
Ito S; Kamei K; Ogura M; Udagawa T; Fujinaga S; Saito M; Sako M; Iijima K
Pediatr Nephrol; 2013 Feb; 28(2):257-64. PubMed ID: 23052656
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes after early treatment with rituximab for Japanese children with cyclosporine- and steroid-resistant nephrotic syndrome.
Fujinaga S; Nishino T; Umeda C; Tomii Y; Watanabe Y; Sakuraya K
Pediatr Nephrol; 2019 Feb; 34(2):353-357. PubMed ID: 30426219
[TBL] [Abstract][Full Text] [Related]
10. Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome?
Delbe-Bertin L; Aoun B; Tudorache E; Lapillone H; Ulinski T
Pediatr Nephrol; 2013 Mar; 28(3):447-51. PubMed ID: 23212560
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of children with steroid-dependent nephrotic syndrome with rituximab].
Huang J; Du J; Wang S; Xiao L; Zhao X
Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):521-4. PubMed ID: 25224058
[TBL] [Abstract][Full Text] [Related]
12. Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome.
Parmentier C; Delbet JD; Decramer S; Boyer O; Hogan J; Ulinski T
Pediatr Nephrol; 2020 Mar; 35(3):455-462. PubMed ID: 31705306
[TBL] [Abstract][Full Text] [Related]
13. Novel use of rituximab for steroid-dependent nephrotic syndrome in children.
Kimata T; Hasui M; Kino J; Kitao T; Yamanouchi S; Tsuji S; Kaneko K
Am J Nephrol; 2013; 38(6):483-8. PubMed ID: 24296765
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery.
Sellier-Leclerc AL; Baudouin V; Kwon T; Macher MA; Guérin V; Lapillonne H; Deschênes G; Ulinski T
Nephrol Dial Transplant; 2012 Mar; 27(3):1083-9. PubMed ID: 21810762
[TBL] [Abstract][Full Text] [Related]
15. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases.
Guigonis V; Dallocchio A; Baudouin V; Dehennault M; Hachon-Le Camus C; Afanetti M; Groothoff J; Llanas B; Niaudet P; Nivet H; Raynaud N; Taque S; Ronco P; Bouissou F
Pediatr Nephrol; 2008 Aug; 23(8):1269-79. PubMed ID: 18465150
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary center and review of the literature.
Van Horebeek I; Knops N; Van Dyck M; Levtchenko E; Mekahli D
Acta Clin Belg; 2017 Jun; 72(3):147-155. PubMed ID: 27409338
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome.
Tellier S; Brochard K; Garnier A; Bandin F; Llanas B; Guigonis V; Cailliez M; Pietrement C; Dunand O; Nathanson S; Bertholet-Thomas A; Ichay L; Decramer S
Pediatr Nephrol; 2013 Jun; 28(6):911-8. PubMed ID: 23340857
[TBL] [Abstract][Full Text] [Related]
18. Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome.
Fujinaga S; Ozawa K; Sakuraya K; Yamada A; Shimizu T
Clin Nephrol; 2016 Jun; 85(6):340-5. PubMed ID: 27125626
[TBL] [Abstract][Full Text] [Related]
19. Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children.
Kamei K; Ishikura K; Sako M; Ito S; Nozu K; Iijima K
Pediatr Nephrol; 2020 Jan; 35(1):17-24. PubMed ID: 30564879
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance.
Guitard J; Hebral AL; Fakhouri F; Joly D; Daugas E; Rivalan J; Guigonis V; Ducret F; Presne C; Pirson Y; Hourmant M; Glachant JC; Vendrely B; Moranne O; Faguer S; Chauveau D
Nephrol Dial Transplant; 2014 Nov; 29(11):2084-91. PubMed ID: 24920841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
